Themis MedicareQ3 FY23

Themis Medicare Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹95.93Market Cap: ₹884 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • Themis Medicare targets a 35% CAGR in consolidated revenue over the next 3 years, aiming to reach around Rs. 1,000 crores.
  • Current year revenue is expected to be close to last year’s level (~Rs. 400 crores), without COVID-related spikes.
  • Growth drivers include:
  • - Significant increase in hospital business through expanded and more productive sales teams.
  • - Increasing revenues from API business backed by new product launches and capacity expansions.
  • - Strategic partnerships and inorganic growth opportunities, especially in hospital and API segments.
  • New products, particularly in APIs, are planned to launch quarterly, starting to contribute to topline within 6 months of exhibit batches.
  • Emphasis on organic growth supported by selective inorganic expansions to sustain targeted high growth.

See what Themis Medicare management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript.
  • However, the management discussed significant CapEx plans of around Rs. 40-45 crores annually for FY23, FY24, and FY25, implying potential funding needs.
  • Themis Lifestyle Private Limited (TSPL) is obligated to pay Themis Medicare Limited Rs. 125 crores as part of a demerger process, which may involve cash and/or share certificates. Themis Medicare, as the holding company, will support TSPL in this activity.
  • No direct statements regarding new debt or equity fundraising rounds were made during the call.
  • The company is also preparing for inorganic growth and significant investments, especially in the API business, which may imply future capital requirements, but no clear plans have been announced.

See what Themis Medicare management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Themis Medicare plans CapEx of around Rs. 40-45 crores per year for FY23, FY24, and FY25.
  • Significant CapEx is required for scaling up the API business to achieve next-level growth.
  • The company is preparing for inorganic growth in API by creating a subsidiary to allow focused expansion.
  • No plans to develop an online portal for hospital orders; existing distribution systems by specialized companies are preferred.
  • Partnership and inorganic opportunities, especially in the hospital business, are being explored to drive growth.
  • R&D investments continue with a focus on new drug delivery systems, APIs, and generic injectables, targeting new product launches every quarter to support revenue growth.

Track Themis Medicare — get its next earnings analysis in your feed

How does Themis Medicare rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisThemis Medicare
Rev 2Mar 1

How does Themis Medicare rank in Pharmaceuticals & Biotechnology?

Compare Themis Medicare against every Pharmaceuticals & Biotechnology company (Q3 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

  • Alpa Laboratorie (Q2 FY27)

    Standalone: ₹3,097.56 lacs . Key results statement takeaways from Alpa Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →